Renaissance Technologies LLC Has Lifted Its Bristol Myers Squibb Co (BMY) Position

April 23, 2018 - By Peter Erickson

Bristol-Myers Squibb Company (NYSE:BMY) LogoInvestors sentiment decreased to 0.94 in Q4 2017. Its down 0.09, from 1.03 in 2017Q3. It fall, as 72 investors sold BMY shares while 526 reduced holdings. 106 funds opened positions while 457 raised stakes. 1.11 billion shares or 0.48% more from 1.11 billion shares in 2017Q3 were reported. Tctc Hldg Ltd holds 1.02% or 318,670 shares. Atlantic Tru Gru Limited Co reported 404,099 shares. Fcg Advisors Lc reported 5,824 shares. Arcadia Inv Management Mi accumulated 1,000 shares. Moreover, Pinnacle Wealth Mngmt Advisory Lc has 0.81% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 23,833 shares. Overbrook Corp invested 0.19% in Bristol-Myers Squibb Company (NYSE:BMY). Montag A And Associate Inc owns 15,563 shares for 0.09% of their portfolio. Meiji Yasuda Asset accumulated 0.31% or 53,144 shares. Hillsdale Management invested in 0.06% or 5,840 shares. Highvista Strategies Ltd invested 0.1% in Bristol-Myers Squibb Company (NYSE:BMY). Voloridge Investment Ltd holds 0.13% or 94,036 shares in its portfolio. Comerica Bancorp has invested 0.26% in Bristol-Myers Squibb Company (NYSE:BMY). Sns Gru Ltd Company has invested 0.08% in Bristol-Myers Squibb Company (NYSE:BMY). Ironwood Mngmt Ltd Liability Corp invested 0.31% in Bristol-Myers Squibb Company (NYSE:BMY). Price T Rowe Assoc Inc Md accumulated 12.21 million shares.

Since December 12, 2017, it had 1 buying transaction, and 1 insider sale for $85,985 activity. Shares for $335,172 were sold by Lynch Thomas J. Jr. on Tuesday, December 12.

Jim Simons increased its stake in Bristol Myers Squibb Co (BMY) by 31.87% based on its latest 2017Q4 regulatory filing with the SEC. Renaissance Technologies Llc bought 3.46 million shares as the company’s stock rose 2.38% while stock markets declined. The hedge fund run by Jim Simons held 14.30M shares of the major pharmaceuticals company at the end of 2017Q4, valued at $876.48 million, up from 10.85 million at the end of the previous reported quarter. Renaissance Technologies Llc who had been investing in Bristol Myers Squibb Co for a number of months, seems to be bullish on the $83.66 billion market cap company. The stock decreased 0.85% or $0.44 during the last trading session, reaching $51.17. About 11.67M shares traded or 30.81% up from the average. Bristol-Myers Squibb Company (NYSE:BMY) has risen 11.37% since April 23, 2017 and is uptrending. It has underperformed by 0.18% the S&P500.

Renaissance Technologies Llc, which manages about $63.99B and $90.70 billion US Long portfolio, decreased its stake in Enova Intl Inc by 287,894 shares to 610,000 shares, valued at $9.27M in 2017Q4, according to the filing. It also reduced its holding in Legacy Tex Finl Group Inc by 232,420 shares in the quarter, leaving it with 654,779 shares, and cut its stake in Twenty First Centy Fox Inc (NASDAQ:FOXA).

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Among 13 analysts covering Bristol Myers (NYSE:BMY), 5 have Buy rating, 1 Sell and 7 Hold. Therefore 38% are positive. Bristol Myers has $78.0 highest and $47 lowest target. $65.60’s average target is 28.20% above currents $51.17 stock price. Bristol Myers had 21 analyst reports since October 25, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Friday, February 16 by Citigroup. Guggenheim maintained the stock with “Buy” rating in Tuesday, April 17 report. The firm has “Buy” rating given on Monday, October 30 by SunTrust. The firm has “Buy” rating by Citigroup given on Wednesday, October 25. The rating was maintained by Bank of America with “Neutral” on Tuesday, April 17. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Neutral” rating by Credit Suisse on Friday, October 27. The stock has “Underperform” rating by BMO Capital Markets on Tuesday, February 6. The rating was upgraded by Morgan Stanley to “Overweight” on Thursday, February 15. The firm has “Sell” rating given on Monday, November 13 by BMO Capital Markets. DZ Bank downgraded the shares of BMY in report on Wednesday, February 28 to “Hold” rating.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: